BioNet l Leading Innovation in Genetically-designed Vaccines Revenue
Biotechnology Research • 
Bang Kachao, Samut Prakan, Thailand • 101-200 Employees
BioNet l Leading Innovation in Genetically-designed Vaccines revenue & valuation
| Annual revenue | $9,154,385 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $29,300,000 |
| Total funding | No funding |
Key Contacts at BioNet l Leading Innovation in Genetically-designed Vaccines
Mukesh Chauhan
Associate Director Of Vaccine Manufacturing
Souad Dapremont
Director Clinical Development
Hong Thai Pham
Ceo
Wassana Wijagkanalan
Director, Discovery
Company overview
| Headquarters | 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Bangkok, 10260, TH |
| Phone number | +6623618110 |
| Websites | |
| NAICS | 541714 |
| Keywords | Technology, R&D, Vaccine, Global Networks |
| Founded | 2001 |
| Employees | 101-200 |
| Socials |
BioNet l Leading Innovation in Genetically-designed Vaccines Email Formats
BioNet l Leading Innovation in Genetically-designed Vaccines uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@bionet-asia.com), used 64.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@bionet-asia.com | 64.3% |
{first name} | john@bionet-asia.com | 35.7% |
About BioNet l Leading Innovation in Genetically-designed Vaccines
BioNet-Asia is a Biotech company with a manufacturing base in Asia and with clinical and business operations in Europe, Asia and Australia. Because we believe sharing vaccine expertise can accelerate the global development of innovative vaccines, we keep on building long-term and fruitful collaborations with universities, research institutes, biotech companies and vaccine manufacturers around the world. In its state-of-the-art vaccine plant in Thailand, BioNet is also building a unique expertise in genetic engineering, protein conjugation, cell-culture and vaccine formulation. The company has developed a broad pipeline with ten products in R&D and clinical stages, including vaccines and recombinant proteins such as CRM197 protein carrier, dengue and hepatitis B vaccines. The company has transferred the technology to produce Hib meningitis vaccine which is now commercialized as a pentavalent vaccine in Asia. BioNet produces recombinant acellular pertussis vaccines using a proprietary technology. Our vaccines are manufactured in accordance to Good Manufacturing Practices (GMP) PIC/S standards, and tested at each manufacturing step as per pharmacopeia requirements using established validated assays in our own quality control and testing facilities. More than 150 highly-skilled employees develop the vaccines of tomorrow, from conception to distribution throughout each development stage: research, non-clinical studies, clinical trials, manufacturing and post-marketing surveillance to ensure the safety, immunogenicity and effectiveness of our vaccines.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
BioNet l Leading Innovation in Genetically-designed Vaccines has 40 employees across 10 departments.
Departments
Number of employees
Funding Data
BioNet l Leading Innovation in Genetically-designed Vaccines has never raised funding before.
United States
United Arab Emirates
New Zealand
South Africa
Frequently asked questions
4.8
40,000 users
